053030.KQ
BINEX Co., Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 6,700.00
−3.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 157.3B | 168.5B | 130.1B | 154.8B | 156.7B |
| Cost of Revenue | 131.6B | 123.4B | 108.8B | 98.2B | 86.5B |
| Gross Profit | 25.7B | 45.1B | 21.3B | 56.7B | 70.2B |
| Operating Expenses | |||||
| R&D Expense | 932.9M | 1.2B | 707.4M | 1.3B | 1.6B |
| SG&A Expense | 39.2B | 35.0B | 36.3B | 53.9B | 50.9B |
| General & Admin Expense | 3.0B | 4.0B | 4.1B | 17.0B | 4.2B |
| Selling & Marketing Expense | 23.6B | 31.0B | 32.2B | 36.8B | 33.9B |
| Other Expenses | 10.2B | 13.5B | 15.1B | (50.1M) | 550.2M |
| Total Operating Expenses | 50.1B | 49.6B | 52.0B | 55.1B | 53.0B |
| Cost and Expenses | 181.7B | 173.0B | 160.8B | 153.0B | 139.5B |
| Operating Income (EBIT) | (24.4B) | (4.5B) | (30.8B) | 1.8B | 17.2B |
| Non-Operating | |||||
| Interest Income | 1.3B | 1.4B | 552.4M | 688.7M | 824.3M |
| Interest Expense | 5.4B | 4.5B | 2.3B | 2.0B | 2.1B |
| Net Interest Income | (4.1B) | (3.2B) | (1.7B) | 688.7M | (1.2B) |
| Other Non-Op Income/Expense | (6.2B) | (1.2B) | (8.2B) | 3.1B | (1.9B) |
| Non-Operating Income (excl Interest) | (2.5B) | — | 5.9B | (5.1B) | (116.1M) |
| EBT (Pre-Tax Income) | (30.6B) | (5.7B) | (38.9B) | 4.9B | 15.2B |
| Income Tax Expense | (1.3B) | (2.4B) | (3.7B) | 311.1M | 2.9B |
| Bottom Line | |||||
| Net Income | (29.3B) | (3.2B) | (35.1B) | 4.7B | 12.4B |
| Earnings from Cont. Ops | (29.3B) | (3.3B) | (35.2B) | 4.6B | 12.4B |
| Earnings from Discont. Ops | — | — | — | (1.1K) | — |
| Bottom Line Net Income | (29.3B) | (3.2B) | (35.1B) | 4.7B | 12.4B |
| Per Share | |||||
| Basic EPS | (₩918) | (₩101) | (₩1,126) | ₩151 | ₩402 |
| Diluted EPS | (₩918) | (₩101) | (₩1,126) | ₩108 | ₩402 |
| Revenue Per Share | ₩4,939 | ₩5,275 | ₩4,177 | ₩5,007 | ₩5,066 |
| Shares | |||||
| Basic Shares Outstanding | 31.8M | 31.9M | 31.1M | 30.9M | 30.9M |
| Diluted Shares Outstanding | 31.8M | 31.9M | 31.1M | 32.5M | 30.9M |
| Profitability Metrics | |||||
| EBITDA | (8.9B) | 9.4B | (24.2B) | 16.8B | 25.6B |
| D&A | 14.6B | 13.9B | 12.4B | 9.9B | 8.3B |
| EBIT | (23.5B) | (4.5B) | (36.6B) | 6.9B | 17.3B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026